Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $158.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 99.76% from the company’s current price.
A number of other research analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. JPMorgan Chase & Co. started coverage on Dianthus Therapeutics in a report on Friday, September 11th. They issued an “overweight” rating and a $135.00 price target for the company. Truist Financial boosted their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Wedbush boosted their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.83.
Check Out Our Latest Analysis on Dianthus Therapeutics
Dianthus Therapeutics Price Performance
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, sell-side analysts expect that Dianthus Therapeutics will post -3.81 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CAO Edward Carr sold 20,000 shares of the stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total value of $2,027,600.00. Following the sale, the chief accounting officer owned 20,000 shares in the company, valued at approximately $2,027,600. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Simon Read sold 2,778 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the sale, the director owned 2,778 shares in the company, valued at approximately $326,553.90. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 242,429 shares of company stock worth $26,118,913 in the last quarter. Company insiders own 3.02% of the company’s stock.
Institutional Trading of Dianthus Therapeutics
Large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Dianthus Therapeutics during the second quarter worth $401,990,000. Wellington Management Group LLP boosted its stake in Dianthus Therapeutics by 24.4% in the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after acquiring an additional 634,099 shares during the period. Jennison Associates LLC acquired a new position in shares of Dianthus Therapeutics during the first quarter worth approximately $40,713,000. Assenagon Asset Management S.A. raised its stake in shares of Dianthus Therapeutics by 160.9% during the third quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after purchasing an additional 451,597 shares in the last quarter. Finally, Spruce Street Capital LP acquired a new stake in Dianthus Therapeutics in the second quarter worth approximately $34,587,464. 47.53% of the stock is owned by institutional investors and hedge funds.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.
Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.
Featured Articles
- Five stocks we like better than Dianthus Therapeutics
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
